Cell therapy for prenatal repair of myelomeningocele: A systematic review - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Current Research in Translational Medicine Année : 2020

Cell therapy for prenatal repair of myelomeningocele: A systematic review

Résumé

Myelomeningocele (MMC) is a spinal cord congenital defect that leads to paraplegia, bladder incontinence and bowel dysfunction. A randomized human trial demonstrated that in utero surgical repair of the MMC defect improves lower limb motor function. However, functional recovery remains incomplete. Stem cell therapy has recently generated great interest in the field of prenatal repair of MMC. In this systematic review we attempt to provide an overview of the current application of stem cells in different animal models of MMC. Publications were retrieved from PubMed and Cochrane Library databases. This process yielded twenty-two studies for inclusion in this review, experimenting five different types of stem cells: human embryonic stem cells, neural stem cells, induced pluripotent stem cells, human amniotic fluid stem cells, and mesenchymal stem cells (MSCs). Rodents and ovine were the two major species used for animal model studies. The source, the aims, and the main results were analyzed. Stem cell therapy appears to be a promising candidate for prenatal repair of MMC, especially MSCs. Further explorations in ovine and rodent models, reporting clinical and functional results, are necessary before an application in humans.
Fichier principal
Vignette du fichier
S2452318620300325.pdf (581.64 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03493103 , version 1 (17-10-2022)

Licence

Identifiants

Citer

A. Dugas, J. Larghero, M. Zérah, Jm. Jouannic, L. Guilbaud. Cell therapy for prenatal repair of myelomeningocele: A systematic review. Current Research in Translational Medicine, 2020, 68, pp.183 - 189. ⟨10.1016/j.retram.2020.04.004⟩. ⟨hal-03493103⟩
22 Consultations
59 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More